Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 15, 2020

SELL
$1.91 - $4.08 $28,096 - $60,016
-14,710 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$0.71 - $4.91 $10,444 - $72,226
14,710 New
14,710 $66,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $340M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Paloma Partners Management CO Portfolio

Follow Paloma Partners Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Paloma Partners Management CO with notifications on news.